OTTAWA, May 21 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS; http://www.htdsmedical.com/) Collagenna Skin care Products has entered into an exclusive distribution agreement with the Malaysian company Medimec www.medimec.com.my
Medimec is a company which manufactures birth control devices which are distributed world wide as well as locally. The company does not represent any other skin care company and felt that the Collagenna Product Line was an excellent opportunity for them to increase revenues locally.
Collagenna CEO Michael Arnkvarn states :" We are very pleased to team up with such a strong partner in Malaysia. Dr Rama has built his business based upon quality before price and this corresponds with our corporate philosophy. Their products are targeted for women and we are confident that their contact base will allow them to build a strong distribution network in a relatively short period of time. Malaysia is our latest international partner and we are discussing with several other potential countries. We are committed to making Collagenna/Melem Secret a truly International Corporation".
Medimec will carry the full Collagenna Skin Care line as well as the Melem Secret Nutriceutical line. Products have been sent to Medimec and have recently been approved for import by the Malaysian Health authorities. Medimec will shortly have a new website www.collagen.my which with feature the Collagenna line and the first major shipment of Collagenna products are scheduled to arrive in Malaysia on May 22, 2010.
The company reminds our shareholders and followers that the company does not subscribe to the PinkSheets.Com Filing Service. Its IR company web site section "CLIENT SUPPORT" TAB www.minamargroup.net or this direct link http://minamarmarketinggroup.helpserve.com/ should be reviewed by its followers for further updates on this and other business matters. Non-newsworthy events are not press released however posted on this separate support sites to keep our followers advised of day-to-day events, and the company corporate web site. For any matters relating to retail investor queries or to send us the company directly a message please click on the "INVESTOR SUPPORT" TAB or this direct link www.minamargroup.net/helpdesk.
To be included in company's email database for press releases, industry updates, and non-weekly activity at the company that may or may not be news released, please subscribe or opt in mailer at www.minamargroup.com/updates.
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only, please contact [email protected]; For any corporate matters, please contact www.minamargroup.com/helpdesk
SOURCE Hard to Treat Diseases
Advertisement
Medimec is a company which manufactures birth control devices which are distributed world wide as well as locally. The company does not represent any other skin care company and felt that the Collagenna Product Line was an excellent opportunity for them to increase revenues locally.
Advertisement
Collagenna CEO Michael Arnkvarn states :" We are very pleased to team up with such a strong partner in Malaysia. Dr Rama has built his business based upon quality before price and this corresponds with our corporate philosophy. Their products are targeted for women and we are confident that their contact base will allow them to build a strong distribution network in a relatively short period of time. Malaysia is our latest international partner and we are discussing with several other potential countries. We are committed to making Collagenna/Melem Secret a truly International Corporation".
Medimec will carry the full Collagenna Skin Care line as well as the Melem Secret Nutriceutical line. Products have been sent to Medimec and have recently been approved for import by the Malaysian Health authorities. Medimec will shortly have a new website www.collagen.my which with feature the Collagenna line and the first major shipment of Collagenna products are scheduled to arrive in Malaysia on May 22, 2010.
The company reminds our shareholders and followers that the company does not subscribe to the PinkSheets.Com Filing Service. Its IR company web site section "CLIENT SUPPORT" TAB www.minamargroup.net or this direct link http://minamarmarketinggroup.helpserve.com/ should be reviewed by its followers for further updates on this and other business matters. Non-newsworthy events are not press released however posted on this separate support sites to keep our followers advised of day-to-day events, and the company corporate web site. For any matters relating to retail investor queries or to send us the company directly a message please click on the "INVESTOR SUPPORT" TAB or this direct link www.minamargroup.net/helpdesk.
To be included in company's email database for press releases, industry updates, and non-weekly activity at the company that may or may not be news released, please subscribe or opt in mailer at www.minamargroup.com/updates.
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only, please contact [email protected]; For any corporate matters, please contact www.minamargroup.com/helpdesk
SOURCE Hard to Treat Diseases
